Saccharomyces boulardii is most commonly used for treating and preventing diarrhea, including infectious types such as rotaviral diarrhea in children. It has some evidence of use for other types of diarrhea, acne, and a digestive tract infection that can lead to ulcers.
Coronavirus disease 2019 (COVID-19): There is no good evidence to support using Saccharomyces boulardii for COVID-19. Follow healthy lifestyle choices and proven prevention methods instead.
How does it work ?
Uses & Effectiveness ?
Likely Effective for
- Diarrhea. Research shows that giving Saccharomyces boulardii to children with diarrhea can reduce how long it lasts by up to 1 day. But Saccharomyces boulardii seems to be less effective than conventional medicines for diarrhea, such as loperamide (Imodium).
- Diarrhea caused by rotavirus. Giving Saccharomyces boulardii to infants and children with diarrhea caused by rotavirus can reduce how long diarrhea lasts by about 1 day.
Possibly Effective for
- Acne. Research shows that taking Saccharomyces boulardii by mouth helps improve the appearance of acne.
- Diarrhea in people taking antibiotics (antibiotic-associated diarrhea). Most research shows that Saccharomyces boulardii can help prevent diarrhea in adults and children being treated with antibiotics. For every 9-13 patients treated with Saccharomyces boulardii during treatment with antibiotics, one less person will develop antibiotic-related diarrhea.
- Infection of the gastrointestinal tract by bacteria called Clostridium difficile. Taking Saccharomyces boulardii along with antibiotics seems to help prevent Clostridium difficile-associated diarrhea from recurring in people with a history of recurrence. Taking Saccharomyces boulardii along with antibiotics also seems to help prevent first episodes of Clostridium difficile-associated diarrhea. But experts don't recommend using Saccharomyces for preventing first episodes.
- A digestive tract infection that can lead to ulcers (Helicobacter pylori or H. pylori). Taking Saccharomyces boulardii by mouth along with standard H. pylori treatment helps treat this infection. About 12 people need to be treated with additional Saccharomyces boulardii for one patient who would otherwise remain infected to be cured. Taking Saccharomyces boulardii also helps prevent side effects such as diarrhea and nausea that occur with standard H. pylori treatment. This might help people finish their standard treatment for H. pylori.
- Diarrhea in people with HIV/AIDS. Taking Saccharomyces boulardii by mouth appears to reduce diarrhea related to HIV.
- A serious intestinal disease in premature infants (necrotizing enterocolitis or NEC). Most research shows that giving Saccharomyces boulardii to preterm infants prevents NEC.
- Travelers' diarrhea. Taking Saccharomyces boulardii by mouth appears to prevent travelers' diarrhea.
Possibly Ineffective for
- Blood infection (sepsis). Research shows that giving Saccharomyces boulardii to preterm infants does not prevent sepsis.
Insufficient Evidence for
- An infection of the intestines that causes diarrhea (cholera). Saccharomyces boulardii does not seem to improve cholera symptoms, even when given with standard treatments.
- Memory and thinking skills (cognitive function). Early research shows that taking Saccharomyces boulardii does not help students do better on exams or reduce their stress.
- A type of inflammatory bowel disease (Crohn disease). Taking Saccharomyces boulardii seems to reduce the number of bowel movements in people with Crohn disease. Early research also shows that taking Saccharomyces boulardii along with mesalamine can help people with Crohn disease stay in remission longer. But taking Saccharomyces boulardii alone does not seem to help people with Crohn disease stay in remission longer.
- Cystic fibrosis. Early research shows that taking Saccharomyces boulardii by mouth does not reduce yeast infections in the digestive tract of people with cystic fibrosis.
- Heart failure. Early research shows that taking Saccharomyces boulardii might improve heart function in people with heart failure.
- High cholesterol. Early research shows that Saccharomyces boulardii does not seem to affect cholesterol levels.
- A long-term disorder of the large intestines that causes stomach pain (irritable bowel syndrome or IBS). Research shows that taking Saccharomyces boulardii improves quality of life in people with diarrhea-predominant or mixed-type IBS. But Saccharomyces boulardii doesn't seem to improve most IBS symptoms such as stomach pain, urgency, or bloating.
- Infection of the intestines by parasites. Early research shows that taking Saccharomyces boulardii by mouth along with antibiotics reduces diarrhea and stomach pain in people with amoeba infections.
- Yellowing of the skin in infants (neonatal jaundice). Some infants develop jaundice after birth due to high bilirubin levels. Giving Saccharomyces boulardii to term infants might prevent jaundice and reduce the need for phototherapy in a small number of these infants. But it's not known if Saccharomyces boulardii reduces the risk of jaundice in at-risk infants. Giving Saccharomyces boulardii to infants along with phototherapy doesn't lower bilirubin levels better than phototherapy alone.
- Infants born weighing less than 2500 grams (5 pounds, 8 ounces). Giving a Saccharomyces boulardii supplement after birth seems to improve weight gain and feeding in preterm infants with low birth weight.
- Excessive growth of bacteria in the small intestines. Early research shows that adding Saccharomyces boulardii to treatment with antibiotics reduces bacteria growth in the intestines better than antibiotics alone.
- A type of inflammatory bowel disease (ulcerative colitis). Early research shows that adding Saccharomyces boulardii to standard mesalamine therapy can reduce symptoms in people with mild-to-moderate ulcerative colitis.
- Canker sores.
- Fever blisters.
- Lactose intolerance.
- Lyme disease.
- Muscle soreness caused by exercise.
- Urinary tract infections (UTIs).
- Yeast infections.
- Other conditions.
Special Precautions and Warnings
Children: Saccharomyces boulardii is POSSIBLY SAFE for children when taken by mouth appropriately. However, diarrhea in children should be evaluated by a healthcare professional before using Saccharomyces boulardii.
Elderly: The elderly might have an increased risk of fungal infection when taking Saccharomyces boulardii. Stay on the safe side and avoid use.
Weakened immune system: There is some concern that taking Saccharomyces boulardii might cause fungemia, which is the presence of yeast in the blood. The actual number of cases of Saccharomyces boulardii-related fungemia is hard to determine. However, the risk seems to be greatest for people who are very sick or who have weakened immune systems. In particular, people with catheters, those receiving tube feeding, and those being treated with multiple antibiotics or antibiotics that work on a wide variety of infections seem to be most at-risk. In many cases, fungemia resulted from catheter contamination by air, environmental surfaces, or hands that have been contaminated with Saccharomyces boulardii.
Yeast allergy: People with yeast allergy can be allergic to products containing Saccharomyces boulardii, and are best advised to avoid these products.
Medications for fungal infections (Antifungals) interacts with SACCHAROMYCES BOULARDII
Saccharomyces boulardii is a fungus. Medications for fungal infections help reduce fungus in and on the body. Taking Saccharomyces boulardii with medications for fungal infections can reduce the effectiveness of Saccaromyces boulardii.
Some medications for fungal infection include fluconazole (Diflucan), terbinafine (Lamisil), itraconazole (Sporanox), and others.
Be watchful with this combination
- For diarrhea in people taking antibiotics (antibiotic-associated diarrhea): 250-500 mg of Saccharomyces boulardii taken 2-4 times daily for up to 2 weeks is most commonly used. In most cases, daily doses do not exceed 1000 mg daily.
- For infection of the gastrointestinal tract by bacteria called Clostridium difficile: For preventing recurrence, 500 mg of Saccharomyces boulardii twice daily for 4 weeks along with antibiotic treatment has been used.
- For a digestive tract infection that can lead to ulcers (Helicobacter pylori or H. pylori): 500-1000 mg of Saccharomyces boulardii daily for 1-4 weeks is most commonly used.
- For diarrhea in people with HIV/AIDS: 3 grams of Saccharomyces boulardii daily.
- For travelers' diarrhea: 250-1000 mg of Saccharomyces boulardii daily for 1 month.
- For diarrhea in people taking antibiotics (antibiotic-associated diarrhea): 250 mg of Saccharomyces boulardii once or twice daily for the duration of antibiotics has been used.
- For diarrhea: For treating acute diarrhea, 250 mg of Saccharomyces boulardii once or twice daily or 10 billion colony-forming units once daily for 5 days has been used. For treating persistent diarrhea, 1750 billion to 175 trillion colony-forming units of Saccharomyces boulardii twice daily for 5 days has been used. For preventing diarrhea in people receiving tube feedings, 500 mg of Saccharomyces boulardii four times daily has been used.
- For diarrhea caused by rotavirus: 200-250 mg of Saccharomyces boulardii twice daily for 5 days has been used.
- For a serious intestinal disease in premature infants (necrotizing enterocolitis or NEC): 100-200 mg/kg Saccharomyces boulardii daily, starting the first week after birth.
Kotowska, M., Albrecht, P., and Szajewska, H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment.Pharmacol.Ther. 3-1-2005;21(5):583-590. View abstract.
Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., and Shafaghi, A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9(8):1832-1833. View abstract.
- Corrêa NB, Penna FJ, Lima FM, Nicoli JR, Filho LA. Treatment of acute diarrhea with Saccharomyces boulardii in infants. J Pediatr Gastroenterol Nutr 2011;53(5):497-501. View abstract.
Adam J, Barret C, Barret-Bellet A, and et al. Essais cliniques controles en double insu de l'Ultra-Levure Lyophilisee. Etude multicentrique par 25 medecins de 388 cas. Gaz Med Fr 1977;84:2072-2078.
Al Faleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014;(4):CD005496. View abstract.
Appel-da-Silva MC, Narvaez GA, Perez LRR, Drehmer L, Lewgoy J. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Med Mycol Case Rep. 2017;18:15-7. View abstract.
Asmat S, Shaukat F, Asmat R, Bakhat HFSG, Asmat TM. Clinical Efficacy Comparison of Saccharomyces Boulardii and Lactic Acid as Probiotics in Acute Pediatric Diarrhea. J Coll Physicians Surg Pak. 2018;28(3):214-217. View abstract.
Atici S, Soysal A, Karadeniz Cerit K, et al. Catheter-related Saccharomyces cerevisiae Fungemia Following Saccharomyces boulardii Probiotic Treatment: In a child in intensive care unit and review of the literature. Med Mycol Case Rep. 2017;15:33-35. View abstract.
Bafutto M, et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalamine and/or Saccharomyces boulardii. Arq Gastroenterol. 2013;50(4):304-309. View abstract.
Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998;105:71-2. View abstract.
Blaabjerg S, Artzi DM, Aabenhus R. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2017;6(4). View abstract.
Bleichner G and Blehaut H. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial [abstract]. Clin Nutr 1994;13 Suppl 1:10.
Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 1997;23:517-23. View abstract.
Born, P., Lersch, C., Zimmerhackl, B., and Classen, M. [The Saccharomyces boulardii therapy of HIV-associated diarrhea]. Dtsch Med Wochenschr 5-21-1993;118(20):765. View abstract.
Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-80. View abstract.
Bourreille A, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 2013;11(8):982-987.
Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993;16:419-25. View abstract.
Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit 2006;12:PI19-22. View abstract.
Carstensen JW, Chehri M, Schønning K, et al. Use of prophylactic Saccharomyces boulardii to prevent Clostridium difficile infection in hospitalized patients: a controlled prospective intervention study. Eur J Clin Microbiol Infect Dis. 2018;37(8):1431-1439. View abstract.
Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infection and Immun 1999;67:302-7. View abstract.
Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000;8:504-5. View abstract.
Cetina-Sauri G and Basto GS. Evaluacion terapeutica de Saccharomyces boulardii en ninos con diarrea aguda. Tribuna Med 1989;56:111-115.
Chang HY, Chen JH, Chang JH, Lin HC, Lin CY, Peng CC. Multiple strains probiotics appear to be the most effective probiotics in the prevention of necrotizing enterocolitis and mortality: An updated meta-analysis. PLoS One. 2017;12(2):e0171579. View abstract.
Chapoy, P. [Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii]. Ann Pediatr.(Paris) 1985;32(6):561-563. View abstract.
Cherifi, S., Robberecht, J., and Miendje, Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004;59(4):223-224. View abstract.
Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679-83. View abstract.
Chouraqui JP, Dietsch J, Musial C, and et al. Saccharomyces boulardii (SB) in the management of toddler diarrhea: a double-blind-placebo controlled study [abstract]. J Pediatr Gastroenterol Nutr 1995;20(4):463.
Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55. View abstract.
Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., and Petrochilou, V. Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum.Dev. 2003;74(2):89-96. View abstract.
Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol. 2015;179:348-50. View abstract.
Cottrell J, Koenig K, Perfekt R, Hofmann R; Loperamide-Simethicone Acute Diarrhoea Study Team. Comparison of Two Forms of Loperamide-Simethicone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial. Drugs R D. 2015;15(4):363-73. View abstract.
Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9. View abstract.
Cremonini, F., Di Caro, S., Santarelli, L., Gabrielli, M., Candelli, M., Nista, E. C., Lupascu, A., Gasbarrini, G., and Gasbarrini, A. Probiotics in antibiotic-associated diarrhoea. Dig.Liver Dis. 2002;34 Suppl 2:S78-S80. View abstract.
Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. Gastroenterol 1994;106:65-72. View abstract.
D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361. View abstract.
Das S, Gupta PK, Das RR. Efficacy and Safety of Saccharomyces boulardii in Acute Rotavirus Diarrhea: Double Blind Randomized Controlled Trial from a Developing Country. J Trop Pediatr. 2016;62(6):464-470. View abstract.
Dauby N. Risks of Saccharomyces boulardii-Containing Probiotics for the Prevention of Clostridium difficile Infection in the Elderly. Gastroenterology. 2017;153(5):1450-1451. View abstract.
Dinleyici EC, Kara A, Dalgic N, et al. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. Benef Microbes. 2015;6(4):415-21. View abstract.
Duman, D. G., Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., Istan, F., Vural, T., Sandkci, M., Isksal, F., Simsek, I., Soyturk, M., Arslan, S., Sivri, B., Soykan, I., Temizkan, A., Bessk, F., Kaymakoglu, S., and Kalayc, C. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol.Hepatol. 2005;17(12):1357-1361. View abstract.
Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infect Dis. 2016;3(1):ofw011. View abstract.
Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic shock due to Sacccaromyces boulardii. Med Mal Infect. 2016;46(2):104-105. View abstract.
Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999;13:1663-8. View abstract.
Elmer GW, McFarland LV. Comment on the lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhea in elderly patients. J Infect 1998;37:307-8. View abstract.
Elmer GW, Moyer KA, Vega R, and et al. Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microecology Ther 1995;25:23-31.
Erdeve, O., Tiras, U., and Dallar, Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop.Pediatr. 2004;50(4):234-236. View abstract.
Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1):e176-191. View abstract.
Flatley EA, Wilde AM, Nailor MD. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis. 2015;24(1):21-4. View abstract.
Florez ID, Veroniki AA, Al Khalifah R, et al. Comparative effectiveness and safety of interventions for acute diarrhea and gastroenteritis in children: A systematic review and network meta-analysis. PLoS One. 2018;13(12):e0207701. View abstract.
Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving ultra-levure therapy. Clin Infect Dis 1998;27:222-3. View abstract.
Gao X, Wang Y, Shi L, Feng W, Yi K. Effect and safety of Saccharomyces boulardii for neonatal necrotizing enterocolitis in pre-term infants: A systematic review and meta-analysis. J Trop Pediatr. 2020:fmaa022. View abstract.
Gaon, D., Garcia, H., Winter, L., Rodriguez, N., Quintas, R., Gonzalez, S. N., and Oliver, G. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 2003;63(4):293-298. View abstract.
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.Dig Dis Sci. 2019. View abstract.
Goldenberg JZ, Lytvyn L, Steurich J, Parkin P, Mahant S, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;(12):CD004827. View abstract.
Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;(5):CD006095. View abstract.
Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8. View abstract.
Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4. View abstract.
Harnett JE, Pyne DB, McKune AJ, Penm J, Pumpa KL. Probiotic supplementation elicits favourable changes in muscle soreness and sleep quality in rugby players. J Sci Med Sport. 2020:S1440-2440(20)30737-4. View abstract.
Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012 9;307(18):1959-69. View abstract.
Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001;39:551-9. View abstract.
Johnston BC, Ma SSY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med 2012;157:878-8. View abstract.
Karbownik MS, Kręczyńska J, Kwarta P, et al. Effect of supplementation with Saccharomyces boulardii on academic examination performance and related stress in healthy medical students: A randomized, double-blind, placebo-controlled trial. Nutrients. 2020;12(5):1469. View abstract.
Kimmey, M. B., Elmer, G. W., Surawicz, C. M., and McFarland, L. V. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig.Dis Sci 1990;35(7):897-901. View abstract.
Kirchhelle, A., Fruhwein, N., and Toburen, D. [Treatment of persistent diarrhea with S. boulardii in returning travelers. Results of a prospective study]. Fortschr Med 4-20-1996;114(11):136-140. View abstract.
Kollaritsch, H., Holst, H., Grobara, P., and Wiedermann, G. [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr.Med 3-30-1993;111(9):152-156. View abstract.
Krammer M, Karbach U. Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption. Z Gastroenterol 1993;31:73-7.
Kurugol, Z. and Koturoglu, G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94(1):44-47. View abstract.
Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37. View abstract.
Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22. View abstract.
Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhea in elderly patients. J Infect 1998;36:171-4. View abstract.
Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., and Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28(6):797-801. View abstract.
Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:S67-9. View abstract.
Martin IW, Tonner R, Trivedi J, et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis. 2017;87(3):286-8. View abstract.
Maupas JL, Champemont P, and Delforge M. [Treatment of irritable bowel syndrome with Saccharomyces boulardii - a double-blind, placebo controlled study]. Médicine et Chirurgie Digestives 1983;12(1):77-79.
McCullough MJ, Clemons KV, McCusker JH, Stevens DA. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998;36:2613-7. View abstract.
McDonald LC, Gerding DN, Johnson S, et al.; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society of Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases 2018;66(7):e1-e48.
McFarland LV, Surawicz C, Greenberg R, and et al. Saccharomyces boulardii and high dose vancomycin treats recurrent Clostridium difficile disease [abstract]. Am J Gastroenterol 1998;93(9):1694.
McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8. View abstract.
McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48. View abstract.
McFarland LV, SurawiczCM, Elmer GW, and et al. Multivariate analysis of the clinical efficacy of a biotherapeutic agent, Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea [abstract]. Am J Epidemiol 1993;138:649.
McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22. View abstract.
McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996;22:200-1. View abstract.
Mourey F, Sureja V, Kheni D, et al. A multicenter, randomized, double-blind, placebo-controlled trial of Saccharomyces boulardii in infants and children with acute diarrhea. Pediatr Infect Dis J. 2020;39(11):e347-e351. View abstract.
Muller J, Remus N, Harms KH. Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995;38:119-23. View abstract.
Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34. View abstract.
Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999;28:930. View abstract.
Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-34. View abstract.
Pletinex M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5. View abstract.
Potts L, Lewis SJ, and Barry R. Randomised double blind placebo controlled study of the ability of Saccharomyces boulardii to prevent antibiotic related diarrhoea [abstract]. Gut 1996;38 (suppl 1):A61.
Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012;107(6):922-31. View abstract.
Remenova T, Morand O, Amato D, Chadha-Boreham H, Tsurutani S, Marquardt T. A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat. Orphanet J Rare Dis 2015;10:81. View abstract.
Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr 2012;79(4):478-82. View abstract.
Riquelme, A. J., Calvo, M. A., Guzman, A. M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., and Labarca, J. A. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin.Gastroenterol. 2003;36(1):41-43. View abstract.
Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. Saccharomyces cerevisiae fungemia in a pediatric patient after treatment with probiotics. Rev Paul Pediatr 2017;35(3):361-4. View abstract.
Roy U, Jessani LG, Rudramurthy SM, et al. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses 2017;60(6):375-380. View abstract.
Ryan JJ, Hanes DA, Schafer MB, Mikolai J, Zwickey H. Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study. J Altern Complement Med. 2015;21(5):288-93. View abstract.
Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000;95:S16-8. View abstract.
Saint-Marc T, Blehaut H, Musial C, and et al. [AIDS-related diarrhea: a double-blind trial of Saccharomyces boulardii]. Semaine Des Hopitaux 1995;71(23-24):735-741.
Saint-Marc T, Rossello-Prats L, and Touraine JL. [Effectiveness of Saccharomyces boulardii in the management of AIDS diarrhea]. Ann Med Interne (Paris) 1991;142(1):64-65.
Saint-Marc, T., Rossello-Prats, L., and Touraine, J. L. [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS]. Ann Med Interne (Paris) 1991;142(1):64-65. View abstract.
Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: A clinical pharmacological approach. Chemotherapy 1995;41:48-81. View abstract.
Seddik H, Boutallaka H, Elkoti I, et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019;75(5):639-645. View abstract.
Serce O, Gursoy T, Ovali F, Karatekin G. Effects of Saccaromyces boulardii on neonatal hyperbilirubinemia: a randomized controlled trial. Am J Perinatol. 2015;30(2):137-142. View abstract.
Shanahan, F. Probiotics in inflamatory bowel disease. Gut 2001;48(5):609. View abstract.
Sheele J, Cartowski J, Dart A, et al. Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera. Pathog Glob Health. 2015;109(6):275-82. View abstract.
Suganthi V, Das AG. Role of Saccharomyces boulardii in reduction of neonatal hyperbilirubinemia. J Clin Diagn Res 2016;10(11):SC12-SC15. View abstract.
Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8. View abstract.
Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989;84:1285-7. View abstract.
Surawicz, C. M. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract.Gastroenterol.Hepatol. 2004;1(1):32-38. View abstract.
Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., and Elmer, G. W. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin.Infect.Dis. 2000;31(4):1012-1017. View abstract.
Szajewska H, Horvath A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(12):1237-1245. View abstract.
Szajewska H, Kolodziej M, Zalewski BM. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update. Aliment Pharmacol Ther. 2020. View abstract.
Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic -associated diarrhoea. Aliment Pharmacol Ther. 2015;42(7):793-801. View abstract.
Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;22:365-72. View abstract.
Tasteyre, A., Barc, M. C., Karjalainen, T., Bourlioux, P., and Collignon, A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb.Pathog. 2002;32(5):219-225. View abstract.
Tempe, J. D., Steidel, A. L., Blehaut, H., Hasselmann, M., Lutun, P., and Maurier, F. [Prevention of diarrhea administering Saccharomyces boulardii during continuous enteral feeding]. Sem.Hop. 5-5-1983;59(18):1409-1412. View abstract.
Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35(12):1355-69. View abstract.
Weber G, Adamczyk A, Freytag S. [Treatment of acne with a yeast preparation]. Fortschr Med 1989;107:563-6. View abstract.
Xu L, Wang Y, Wang Y, et al. A double-blinded randomized trial on growth and feeding tolerance with Saccharomyces boulardii CNCM I-745 in formula-fed preterm infants. J Pediatr (Rio J). 2016;92(3):296-301. View abstract.
Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.